Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PHD finger protein 3 (PHF3) is a nuclear transcription regulator containing a PHD finger domain, the SPOC domain, and other chromatin-interacting features[1][8]. PHF3 binds specifically to RNA polymerase II phosphorylated at serine-2 within its C-terminal domain (CTD), thus reading the CTD code during transcription elongation[1][2][6][8]. This interaction modulates transcriptional activity and mRNA decay, helping restrict premature neuronal gene expression in stem cells and enabling proper neuronal differentiation[1][2]. Loss or mutation of PHF3 is linked to increased stability and expression of neuronal transcripts, impaired neurogenesis, and has been correlated with certain cancers (glioblastoma) and neurodevelopmental disorders (autism)[2][4]. PHF3 is also associated with retinitis pigmentosa and cone-rod dystrophy[4]. No approved drugs directly target PHF3, though it is of interest for further research as a disease-linked transcriptional regulator.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PHD finger protein 3 (PHF3).